Last reviewed · How we verify
insulin eye drops
Insulin eye drops deliver insulin topically to the ocular surface to promote corneal epithelial healing and reduce inflammation.
Insulin eye drops deliver insulin topically to the ocular surface to promote corneal epithelial healing and reduce inflammation. Used for Corneal epithelial defects and corneal healing, Dry eye disease.
At a glance
| Generic name | insulin eye drops |
|---|---|
| Sponsor | Hotel Dieu de France Hospital |
| Drug class | Topical peptide therapeutic |
| Target | Insulin receptor (IGF-1R cross-reactivity possible) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Insulin has been shown to have regenerative and anti-inflammatory properties in ocular tissues. When applied as eye drops, insulin may stimulate epithelial cell growth factors and reduce inflammatory cytokines at the ocular surface, potentially accelerating corneal healing and improving symptoms in dry eye or corneal damage conditions.
Approved indications
- Corneal epithelial defects and corneal healing
- Dry eye disease
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Foreign body sensation
Key clinical trials
- Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye (PHASE1, PHASE2)
- Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry Eye (PHASE4)
- Impact of Filtration on Autologous Serum Eye Drops (NA)
- Topical Insulin for Glaucoma (PHASE1)
- Efficacy of Topical Insuline in Corneal Epithelial Healing Post PRK (PHASE4)
- Evaluating the Efficacy of Topical Insulin for the Restoration of Ocular Surface Interface in Dry Eye Disease. (PHASE4)
- Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial (PHASE3)
- Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin eye drops CI brief — competitive landscape report
- insulin eye drops updates RSS · CI watch RSS
- Hotel Dieu de France Hospital portfolio CI